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Autophagy is dysregulated in cancer and might be involved in ovarian carcinogenesis. BECLIN-1, a protein that interacts with
either BCL-2 or PI3k class III, plays a critical role in the regulation of both autophagy and cell death. Induction of autophagy is
associated with the presence of vacuoles characteristically labelled with the protein LC3.We have studied the biological and clinical
significance of BECLIN 1 and LC3 in ovary tumours of different histological types. The positive expression of BECLIN 1 was well
correlated with the presence of LC3-positive autophagic vacuoles and was inversely correlated with the expression of BCL-2. The
latter inhibits the autophagy function of BECLIN 1.We found that type I tumours, which are less aggressive than type II, were more
frequently expressing high level of BECLIN 1. Of note, tumours of histologic grade III expressed low level of BECLIN 1. Consistently,
high level of expression of BECLIN 1 and LC3 in tumours is well correlated with the overall survival of the patients.The present data
are compatible with the hypotheses that a low level of autophagy favours cancer progression and that ovary cancer with upregulated
autophagy has a less aggressive behaviour and is more responsive to chemotherapy.
1. Introduction
Epithelial ovary cancers (EOCs) represent the vast majority
(approximately 90%) of all ovary tumours. Based on mor-
phological criteria, EOCs are classified as serous (of low and
high grade), clear cell, endometrioid, mucinous transitional
(Brenner type), mixedmesodermal, and undifferentiated his-
tologic subtypes [1]. The histogenesis of EOC is still debated.
Very recently, the traditional view that EOCs arise from the
metaplastic transformation of the mesothelium overlying the
ovaries has been challenged by a new paradigm suggesting
that these carcinomas indeed arise in extraovarian sites and
involve the ovaries secondarily [1]. Based on genetic and
clinical features, ovarian carcinomas are classified as type I
that comprise the low-grade serous, low-grade endometrioid,
clear cell, mucinous, and transitional (Brenner) histologic
types and as type II that comprise the high-grade serous,
high-grade endometrioid, undifferentiated, andmixedmeso-
dermal histologic types [1]. Type I ovarian carcinomas are
geneticallymore stable and clinically indolent and less aggres-
sive than type II ovarian carcinomas [1].
Ovarian cancer ranks as the sixth to eighth most frequent
cancer in developed countries [2] and, in spite of the recent
progresses made in understanding the genetic and biologic
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bases [3, 4], it remains the most lethal among all the gynae-
cologic malignancies, with a 5-year survival of less than 30%
[5]. Bad prognosis is essentially due to the fact that diagnosis
of ovarian cancers often occurs at a late stage (because of
the lack of precocious alarming symptoms) and also due to
the recurrence of chemoresistant tumours. Therefore, new
biomarkers for early detection and for monitoring the pro-
gression of ovarian cancers [6], as well as new therapeutic
strategies that could specifically target the chemoresistant
clones [3, 4], are needed.
Autophagy, a lysosomal-dependent pathway for the
degradation of redundant or damaged cell components, has
recently been suggested to play a role in ovarian carcinogen-
esis and to be a potential therapeutic target to combat this
cancer [7]. Autophagy begins with the production of double-
membrane vacuoles (named autophagosomes) that entrap
the material to be degraded and eventually fuse with lyso-
somes (reviewed in [7]). The autophagosomes are charac-
teristically marked by the presence of protein LC3 (deriv-
ing from posttranslational modifications of a microtubule-
associated protein precursor) on their membranes [8].
Among the many proteins that directly or indirectly regulate
the autophagy process, BECLIN 1 seems to be of particular
relevance in ovarian carcinogenesis. BECLIN 1 was initially
isolated as an interactor of the oncogenic antiapoptotic pro-
tein BCL-2, and it was reported to be deleted in up to 75% of
human ovarian cancers [9, 10]. The monoallelic deletion of
BECLIN 1 in mice caused the spontaneous development of
tumours, including ovarian cancer, in association with
reduced autophagy [11].
To trigger autophagy, BECLIN 1 must release BCL-2 and
form dimers which interact with PI3-kinase class III (or
Vps34), thus forming an oligomeric complex that can be evi-
denced by immunohistochemistry or immunofluorescence as
definite spots in the cytoplasm [12, 13]. Autophagy-active
BECLIN 1 has been proposed as a potential prognostic
biomarker in several tumours [13–15]. However, the prognos-
tic significance of BECLIN 1 expression in ovarian carcino-
mas appears controversial. Shen et al. [16] found that BECLIN
1 expression was significantly higher in benign and border-
line ovarian tumours than in malignant EOC, which was
consistent with the view that a decreased capacity of auto-
phagy could favour tumorigenesis in the ovary. Recently, this
same group confirmed this observation in a larger cohort
of patients and also found that low expression of BECLIN 1
and high level of expression of BCL-2 were associated with
advanced clinical stage at diagnosis and poor prognosis [17].
In contrast, another study found that BECLIN 1 expression
was increased in malignant versus benign ovary tissues
and that such high expression was associated with worse
prognosis [18]. Increased expression of BECLIN 1 was found
also to be associated with the most aggressive endometrioid
adenocarcinomas and poor 5-year overall survival, probably
because of concomitant tumour hypoxia [19]. In this same
line, it was reported that the high expression of LC3A, the
marker of autophagosomes, was associated with hypoxia and
poor prognosis in clear cell, but not other examined subtypes,
ovarian cancers [20].
In this work, we assessed by immunohistochemistry and
immunofluorescence the expression of BECLIN 1 and of LC3
in various histologic subtypes of ovarian cancer. The ratio of
BECLIN 1 and BCL-2 expression was also determined by
western blotting in some selected cases. We noted that type I
ovarian carcinomas that are clinically less aggressive than
type II weremore frequently expressing high level of BECLIN
1. Conversely, low level of BECLIN 1 expression correlated
with histologic grade III tumours. No statistically significant
association with patient survival was found in the cases
judged negative for BECLIN 1 expression. On the other
hand, granular-like positivity of BECLIN 1 and LC3, which is
indicative of ongoing autophagy, was more frequently
observed in tumours from patients with a better survival.
These data suggest that ovarian cancer progression is facili-
tated by low level of intrinsic autophagy and that ovarian can-
cers with upregulated autophagy aremore likely to respond to
therapeutic treatments and to progress more slowly.
2. Materials and Methods
2.1. Patients, Therapeutic Treatments, and Tissue Collection.
The present retrospective study includes 61 cases of ovarian
carcinomas selected in the years 1999–2004 from the archived
materials of the Department of Gynecology of Universita`
di Torino (Italy). All cases were classified according to
the current WHO Classification of Neoplasms. All patients
underwent surgery. With the exception of those staged as
pT1/G1 (for whom no further treatment was required), all
patients were thereafter subjected to a standard chemother-
apy regimen which included Carboplatin AUC 5/6 and
Paclitaxel 175mg/mq every 3 weeks for 6 cycles, outside
of clinical trials. Follow-up ended in 2009. Biopsies were
obtained at the time of the first surgery. Formalin-fixed
paraffin-embedded tissue sections were prepared and used
for diagnostic purposes and for the present investigation.
No oral or written informed consent was obtained from the
patients for the use of these retrospective samples, since it
was not deemed necessary by the local ethics committee. All
samples were treated anonymously.
2.2. Tissue Immunoreactivity for BECLIN 1, LC3, and BCL-2.
Immunohistochemistry and immunofluorescence were per-
formed in deparaffinized tissue sections following our pub-
lished protocol [13]. Proteins of interest were revealed by
subsequent incubation of the tissue with a primary (first step)
and a secondary (second step) antibody. In the first step the
following primary antibodies, either alone or in appropriate
combination, were used: (a) anti-BECLIN 1 mouse mono-
clonal (BD Pharmingen, San Diego, CA; dilution 1 : 100) or
anti-BECLIN 1 rabbit polyclonal (Santa Cruz Biotechnology,
Santa Cruz, CA; dilution 1 : 100); (b) anti-LC3 rabbit
polyclonal (Novus Biological, Littleton, Colorado; dilution
1 : 500); (c) anti-BCL-2 mouse monoclonal (Santa Cruz Bio-
technology, Santa Cruz, CA; dilution 1 : 100). Appropriate
secondary antibodies, goat-anti-mouse IgG or goat-anti-
rabbit IgG (Sigma-Aldrich Inc., St. Louis, MO; dilution
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1 : 200), labelled with horse-radish-peroxidase (for immuno-
histochemistry) or with FITC or Texas Red fluorescent dye
(for immunofluorescence), were used in the second step.
The section subjected to immunofluorescence were also
stained with the fluorescent dye 4-6-diamidino-2-pheny-
lindole-dihydrochloride (DAPI, 1 : 500 from a stock solution
20mg/mL; 1 h) to evidence the nucleus. The sections were
mounted with Slow-FAD (Light AntiFADE kit, Molecular
Probes Invitrogen, Carlsband, CA, USA), observed under a
fluorescencemicroscope (Leica DM1600, LeicaMicrosystem,
Heidelberg, Germany) and representative areas were imaged
with a digital camera.
2.3. Evaluation of Tissue Positivity for Autophagy Proteins.
To assess the immunoreactivity for BECLIN 1 and for LC3
proteins, at least five fields randomly chosen (approximately
5000 cells) per section were evaluated independently by
three investigators (GV and CI for IHC; GN and CI for IF).
The sample was considered positive only when the
immunoreaction presented with a granular-like pattern.
For this purpose, high magnification images were used. Only
neoplastic cells were counted.The proportion of positive cells
over the total number of cells present in the imaged areas
were expressed as percentage. A final hybrid score (H) was
assigned to each sample, based on the product of a 0–3 scale of
staining intensity and of the percentage of positive cells (0–
100%), with a possible range of results from 0 to 300. Each
biopsy was tested at least two times.
2.4. Tissue Western Blotting of BECLIN 1 and of BCL-2. For
some samples a frozen biopsy was also available and used for
western blotting detection of BECLIN 1 and of BCL-2, follow-
ing our published protocol [13]. Essentially, a piece of frozen
biopsy was homogenized by several cycles of freeze-thawing
and sonication in a phosphate buffer containing detergents
and protease inhibitors. A 30𝜇g of protein homogenate was
resolved by SDS-polyacrylamide gel electrophoresis and
thereafter electrotransferred into a nitrocellulose membrane.
Standard procedure for western blotting was used [21] to
detect BECLIN 1 and BCL-2, respectively, with a monoclonal
antibody (BD Pharmingen; dilution 1 : 250) and a rabbit poly-
clonal antiserum (Santa Cruz Biotechnology; dilution 1 : 100).
After stripping, the filter was reprobed to detect actin, used
as a loading marker. Appropriate peroxidase-conjugated sec-
ondary antibodies (purchased from Sigma-Aldrich; dilution
1 : 20.000)were used to reveal the immunocomplexes through
peroxidase-induced chemiluminescence reaction (Biorad,
Hercules, CA, USA).
2.5. Statistical Analysis. BECLIN 1 and LC3 granular-like
positivity as assessed by IHC and/or IF was correlated to the
clinical outcome referred to as complete remission (CR) and
overall survival (OS) at 5 years. The odds ratio, the relative
risk, and the Chi-square were calculated using the Microsoft
Excel XLStat 2010 software. The Fisher’s exact test was also
employed for pairwise comparison of distributions of catego-
rized groups. A 𝑃 value lower than 0.05 was taken to indicate
data statistically significant.
3. Results
3.1. Histologic Type andMain Clinical Characteristics of Ovary
Carcinomas Included in the Study. This retrospective study
included 61 cases of ovary carcinomas of various histologic
types selected fromour archivedmaterials.The tumours were
grouped as type I and type II [1]. All patientswere subjected to
surgery and chemotherapy, following standard criteria based
on clinical stage and patient performance status. The follow-
ing information was available: clinical stage at first diagnosis,
histologic type, objective response to chemotherapy, and
clinical outcome. Response to therapy regimen was evaluated
according to the international guidelines. Clinical outcomes
were classified as complete remission (CR) or alternatively as
not evidence of disease (NED), that is, disappearance of any
evidence of disease during the follow-up or for at least four
years), partial remission (PR, ≥ 50% decrease of tumour
lesions for at least 24 months), and DOD (dead of disease).
Overall survival (OS) was calculated from the time of first
diagnosis to the end of the follow-up, which terminated in
2009. The database with the histologic, clinical, and patients’
main information of the cases included in the present study is
reported in Supplementary Table ST1 (see Supplementary
Table ST1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/462658).
3.2. Immunodetection of BECLIN 1 in Ovary Cancer Tissues.
The presence and the cytoplasmic distribution of BECLIN 1
were first analysed by immunohistochemistry (IHC) in
paraffin-embedded tissue sections of ovary carcinomas.
BECLIN 1 immunoreactivity in tumour cells presented as a
faintly detectable staining diffused in the cytoplasm or as
discrete stained puncta (referred to as granular-type) clearly
evident in the vicinity of the nucleus.The former immunore-
activity pattern was considered as negative, whereas the latter
was considered as positive in terms of BECLIN 1macroaggre-
gates and indicative of active autophagy. A parallel analysis of
BECLIN 1 expressionwas conducted by immunofluorescence
(IF) in the same sections. Results from both techniques over-
lapped, though some cases judged negative on IHC appeared
faintly positive on IF, owing to the highest sensitivity of the
latter technique. Representative images of BECLIN 1 expres-
sion and cellular distribution, as assessed by IHC and IF in
selected cases, are shown in Figures 1 and 2, respectively.
3.3. Correlation of BECLIN 1 Expression with Histologic Type.
Based on the proportion of BECLIN 1-positive cells within the
tumour tissue, the samples were initially stratified into four
ranges of positivity: <10%; 10–20%; 20–40%; >40%. Based on
the intensity (on a 0 to 3 scale) and on the proportion of the
cells positive for BECLIN 1 as assessed by IHC, hybrid score
(H) was assigned to each section independently by two
pathologists (GV andCI). To indicate positivity for BECLIN 1
expression the final thresholdwas set at≥20%of cells showing
a granular-like staining of intensity ≥2 (H ≥ 40). A high
proportion of BECLIN 1-positive cells was reported in 41 out
of 61 tumours. Of note, while type II tumours showed an
approximately equal distribution of BECLIN 1 positivity (11
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Figure 1: Immunohistochemical detection of BECLIN 1. Selection of representative cases. The histologic type and the clinical outcome (CR:
complete remission; DOD: dead of disease) are indicated. Magnification 220x.
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Figure 2: Immunofluorescence detection of BECLIN 1. Selection of representative cases. The histologic type and the clinical outcome (CR:
complete remission; DOD: dead of disease) are indicated. The nuclei are evidenced by DAPI staining.
positive and 8 negative), as many as 20 out of 23 type I
tumours were found highly expressing BECLIN 1. More in
detail, >20% BECLIN 1-positive cells (>40H) were found in
the majority of endometrioid adenocarcinomas (11/13) and of
serous cystadenocarcinomas (19/27). However, there was no
statistically significant association between the extent of
BECLIN 1-positive cells and a particular histologic type of
ovarian cancer (Table 1).
3.4. BECLIN 1 Expression Correlates with Histologic Grading
but Not with Pathological Staging at Diagnosis. Next, we
looked for any correlation between the extent of BECLIN 1
expression and the aggressiveness of ovarian cancers as mir-
rored by the histologic grading and the pathological stage at
diagnosis. It was found thatwhile tumourswith a high expres-
sion of BECLIN 1 were equally distributed in I-II and III
grade, tumours negative or low expressing BECLIN 1 more
frequently (18 out of 20) belonged to grade III (Table 2(a)).
This correlation was statistically significant (𝑃 = 0.004).With
regard to the pathological staging, it was found that of the 20
carcinomas with <20% of BECLIN 1-positive cells, 10 were
classified as I-II stage and 10 as III-IV stage; of the 41
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Table 1: Distribution of BECLIN 1 positivity (in terms of H ≥ 40)
among ovarian carcinoma histologic types.
BECLIN 1 positive Yes No Number of cases
Histologic type I
Serous (low grade) 8 0 8
Endometrioid (low grade) 8 0 8
Clear cell 2 2 4
Mucinous 2 1 3
Transitional (Brenner) 0 1 1
Histologic type II
Serous (high grade) 11 8 19
Endometrioid (high grade) 3 2 5
Undifferentiated 6 5 11
Mixed mesodermal 1 1 2
Total 41 20 61
Table 2: Correlation of BECLIN 1 positivity (in terms of H ≥ 40)
with clinical-pathological characteristics. (a) Statistical correlation
with histologic grade; (b) statistical correlationwith pathologic stage
at diagnosis.
(a)
Grade I-II III Number of cases
BECLIN 1
+ 21 20 41
− 2 18 20
Total 23 38 61
Chi-square = 8.05
DF = 1
P = 0.0046
Fischer’s test P = 0.002.
(b)
Stage I-II III-IV Number of cases
BECLIN 1
+ 24 17 41
− 10 10 20
Total 34 27 61
Chi-square = 0.13
DF = 1
P = 0.7
Fischer’s test P = 0.59.
carcinomas with ≥20% BECLIN 1-positive cells, 24 were of
I-II stage and 17 of III-IV stage (Table 2(b)). No significant
correlation was found between the positivity for BECLIN 1
and the pathological stage (𝑃 = 0.7). On the whole, these
findings indicate that the absence of BECLIN 1 expression,
which likely determines defective autophagy, favours a more
malignant phenotype of the tumour, though other factors,
independent of the intrinsic autophagy capacity, influence the
evolution of the disease and the accompanying general
symptoms that lead to the first diagnosis.
3.5. Ovarian Carcinomas Highly Expressing BECLIN 1 Asso-
ciate with Better Patient’s Clinical Outcome. We asked about
the clinical significance of BECLIN 1 expression in terms of
the impact on the posttherapy outcome. The patients were
all subjected to surgical removal of the ovaries and annexes,
followed by a standard chemotherapeutic treatment protocol.
Chemotherapeutics included Carboplatin and Paclitaxel. For
seven patients, staged as pT1 and bearing a G1 tumour, no
adjuvant chemotherapy was administered.We first correlated
the expression of BECLIN 1 with the patient’s overall survival
(OS) at 5 years. Patients bearing a tumour with a low
expression of BECLIN 1 (H < 40) showed no differences in
terms of OS, with 9 being dead and 11 still alive at the time
of the end of the follow-up (Table 3(a)). By contrast, a sta-
tistically significant correlation was found between the high
expression of BECLIN 1 (i.e., tumours with ≥20% of positive
cells) and patient’s OS. In particular, of the 41 patients bearing
a tumour highly expressing BECLIN 1, 34 (∼83%) were still
alive at the end-point of the study and only 7 (17%) died
during the observation period. These correlations were sta-
tistically significant (𝑃 < 0.03). We then considered the
clinical outcome separately as CR (or NED), PR, and DOD to
see any correlation with the expression of BECLIN 1.
Amongst the 61 cases, 32 patients (52%) underwent CR. Of
these, as many as 24 (75%) were bearing an ovary cancer with
≥20% BECLIN 1-positive cells. Conversely, only 8 out of 32
(25%) patients in CR were bearing a cancer with a ≤20% of
BECLIN 1-positive cells (Table 3(b)). PR was more frequently
observed in the group of patients bearing a cancer with a
high proportion of BECLIN 1-positive tumour cells than in
the group of patients bearing a BECLIN-negative cancer (25%
versus 15%), and DOD was also less frequent in the former
than in the latter group of patients (17% versus 45%). These
correlations were, however, not statistically significant (𝑃 <
0.06). Altogether, these observations support the content that
the high expression of BECLIN 1 in ovarian carcinomas
associates with a better prognosis. However, no correlation
with the clinical outcome was found in the group of patients
bearing a tumour negative or low expressing BECLIN 1. We
have also performed the analysis of the overall survival
probability of the patients by the Kaplan-Meier method
(Supplementary Figure 1, SF1). Log-rank test indicated that
the association of high expression of BECLIN 1 in the tumour
with a good prognosis was statistically significant. Yet, a larger
number of patients should be studied in order to substantiate
the above finding.
3.6. BECLIN 1 and LC3Double Positivity Predicts a Favourable
Prognosis in Ovarian Cancer. In autophagy active cells, the
microtubule-associated LC3 protein is posttranslationally
translocated into the membranes of autophagosomes [8].
Therefore, the detection of a granular-like staining of LC3
can be assumed bona fide as the proof of the presence
of autophagic vacuoles (either autophagosomes or autopha-
golysosomes) in the cell. We analysed by immunofluores-
cence the expression of LC3 in selected BECLIN 1-positive
(𝑛 = 30) and BECLIN 1-negative cases (𝑛 = 12). Cells were
considered positive for ongoing autophagy when showing a
granular-like staining for LC3 and the tumourwas considered
autophagy-active when ≥20% of the cells were LC3 positive.
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Figure 3: Immunofluorescence staining of LC3 in ovarian cancer tissue sections. Selection of representative cases. The histologic type, the
positivity for BECLIN 1 aggregates, the percentage of cells positive for vacuolar LC3, the clinical outcome (CR: complete remission; PR: partial
remission; DOD: dead of disease), the pathological stage, and the histologic grade are reported. The nuclei are evidenced by DAPI staining.
Table 3: Correlation of BECLIN 1 expression with clinical outcome
in patients.
(a)
Clinical outcome Survivors DOD Number of cases
BECLIN 1
+ 34 7 41
− 11 9 20
Total 45 16 61
Chi-square = 4.07
DF = 1
P = 0.04
Fischer’s test
P = 0.03.
(b)
Clinical outcome CR PR DOD Number of cases
BECLIN 1
+ 24 10 7 41
− 8 3 9 20
Total 32 13 16 61
Chi-square = 5.4
DF = 2
P = 0.066.
Examples of LC3 staining in BECLIN 1-positive tumour cells
are shown in Figure 3. With a few exceptions, cases judged
positive for BECLIN 1 were highly positive also for LC3.
On the whole, we found a concordance of 70% between the
expression of both BECLIN 1 and LC3.
To further substantiate the involvement of autophagy in
the progression and chemotherapeutic response of ovarian
carcinomas, we correlated the expression of LC3 with the
clinical outcome. When restricted to the group of BECLIN
1-positive tumours, it was found that 20 out of 21 patients
bearing a tumour also positive for LC3 were still alive, while 6
out of 9 of those patients bearing a tumour negative for LC3
were DOD, at 5 years after diagnosis (Table 4(a)). These cor-
relations were statistically significant (𝑃 < 0.0002). Statistics
was then applied to the whole group of tumours analyzed
for LC3 positivity, including both the BECLIN 1 positive and
BECLIN 1 negative. On the whole, 23 out of 24 patients with
an LC3-positive tumour were still alive, while 11 out 18
patients with an LC3-negative tumour were DOD, at 5 years
after diagnosis (Table 4(b)). Of note, in this case the correla-
tions were even more significant (𝑃 < 0.0002).
3.7. Coexpression of BECLIN 1 and BCL-2 in relation to
Autophagy in Ovarian Cancers. The interaction of BECLIN 1
with BCL-2 abrogates the induction of autophagy [22]. On
the other hand, high expression of BCL-2 inhibits not only
BioMed Research International 7
Table 4: Correlation of LC3 expression with patients overall
survival. (a) Group of BECLIN 1 positive tumours; (b) group of
BECLIN 1 positive and negative tumours.
(a)
% LC3 positive Survivors 5 y DOD Number of cases
<20% 3 6 9
≥20% 20 1 21
Total 23 7 30
Chi-square = 13.5
DF = 1
P = 0.0002.
(b)
% LC3 positive Survivors 5 y DOD Number of cases
<20% 7 11 18
≥20% 23 1 24
Total 30 12 42
Chi-square = 16.34
DF = 1
P = 0.0001.
autophagy but also apoptosis, thus influencing the cytotoxic
response of ovarian cancer cells to chemotherapeutics [17, 21].
Thus, evaluating the level of expression of BECLIN 1 may not
be sufficient to draw conclusions about the capacity of the cell
to activate autophagy. We have analysed by western blotting
the expression of BECLIN 1 and of BCL-2 in a small subset
of carcinomas for which the frozen biopsy was available
(representative cases are shown in Figure 4). In general, the
expression of these proteins was inversely related. To seek for
a functional relationship between the two proteins, we per-
formed the immunostaining of BECLIN 1, BCL-2, and LC3 in
two paradigmatic situations among the cases analysed by
western blotting. In case 1, the expression of BCL-2 was quite
high, which could account for inhibition of BECLIN 1 proau-
tophagic activity, and in fact this tumourwas negative for LC3
staining (Figure 5(a)). On the opposite, BCL-2 and BECLIN
1 were not detectable (by western blotting) in the tumour
case 2, and in spite of this the tumour was intensely LC3
positive (Figure 5(b)), which possibly was associated with
BECLIN 1-independent autophagy.
4. Discussion
Autophagy, a cell homeostatic process for the lysosome-
driven degradation of aged, damaged, and redundant self-
constituents, may either suppress or facilitate carcinogenesis
[7, 23]. The heterozygous deletion of the autophagy gene
BECLIN 1 in transgenic mice predisposes to the development
of spontaneous tumours, including ovarian cancers [11, 24].
Accordingly, the expression of the BECLIN 1 protein and also
of the autophagosome protein LC3 was found much lower
in malignant ovarian cancers compared to benign ovary
epithelial tissues [16, 17]. In our series, we also have found
that 18 out of 20 ovarian cancers of histologic grade III were
negative or low expressing BECLIN 1. This is consistent with
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Figure 4: Western blotting analysis of the expression of BECLIN
1 and of BCL-2 proteins in ovarian carcinomas. Selection of
representative cases. Tissue homogenates were subsequently probed
for BECLIN 1, BCL-2, and actin (the latter was used as reference
of homogenate protein loading). The molecular weight of proteins
detected with the specific antibodies is indicated. Histologic type: S:
serous; U: undifferentiated; E: endometrioid.
the view that defective autophagy might favour cancer pro-
gression. In this same line, a decreased level of BECLIN 1
expression, especially in conjunction with increased expres-
sion of BCL-xL, was correlated with poor prognosis in ovar-
ian cancer bearing patients [17]. Here we have analysed the
tissue expression of BECLIN 1 in a series of 61 cases of
ovarian carcinomas of various histologic types. BECLIN 1
staining presented with either a cytoplasmic diffused pattern
(regarded as negative) or a granular-like pattern (regarded as
positive). The latter likely reflected the engagement of
BECLIN 1 in the oligomeric interactomewith PI3-kinase class
III [12], which preludes to the initiation of autophagy [22].
Fourteen (of the 61) cancers examined showed positive for
BECLIN 1 in a percentage of cells ranging from 20% to 90%.
The expression of BECLIN 1 was not correlated with patient’s
age at the time of diagnosis, nor was it correlated with a
particular histologic type. It is to be noted, however, that in
our series some histologic types were underrepresented so
that no conclusion could be drawn with regard to the associ-
ation between autophagy and histotypes. On the other hand,
being autophagy, an evolutionary conserved and ubiquitous
process, it is conceivable that it is not restricted to a particular
subtype of cancer. Setting the cut-off at 20% of positive cells
(in terms of BECLIN 1 macroaggregates), a positive cor-
relation was found between negative expression and high
histologic grade. In general, the clinically indolent type I
tumours were more frequently expressing BECLIN 1 at high
level.
However, no statistically significant correlationwas found
between the positive expression and the pathological stage at
diagnosis. Thus, while defective autophagy likely favours the
emergence of highlymalignant clones, other factors influence
the general evolution of the disease in the patient.
Tumours negative for BECLIN 1 showed no correlation
with prognosis (11 survivors and 9DOD), whereas of the 41
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Figure 5: Immunofluorescence staining of LC3 and BCL-2. Selection of representative cases.The histologic type, the positivity for BECLIN 1
aggregates, the clinical outcome (CR: complete remission; DOD: dead of disease), the pathological stage, and the histologic grade are reported.
The nuclei are evidenced by DAPI staining.
patients bearing a BECLIN 1-positive tumours as many as 34
showed a favourable prognosis (24 CR and 10 PR). Seen from
a different point, of the 32 patients that underwent CR as
many as 24were bearing a BECLIN 1-positive cancer and only
8 were bearing a BECLIN 1-negative cancer. These correla-
tions were statistically significant. While our data seem to be
consistent with the findings reported by Shen et al. [16] and
Lin et al. [17], other authors have reported opposite findings.
In one study [18], the expression of BECLIN 1 was inversely
correlated with the histologic grade of differentiation of ovar-
ian carcinomas and the high level of BECLIN 1 expressionwas
associated with a lower relapse-free survival rate of the
patients. High level of BECLIN 1 was also found associated
with invasive endometrioid cancers and poor 5-year survival
[19]. However, both in these studies BECLIN 1 was not an
independent prognostic factor. In our series, we have indeed
observed that seven patients bearing a cancer with >20% of
BECLIN1-positive cells deceasedwithin the follow-up period.
Assuming that BECLIN 1 main function was to drive
autophagy and that autophagy was playing a positive role in
the response to chemotherapy treatments, we considered the
possibility that failure in the chemotherapy response in those
patients could arise from impaired (or insufficient) induction
of autophagy in the tumour cells expressing BECLIN 1. To
better detect autophagy active cells in the tumour, we stained
the cells for LC3, an autophagosomal protein considered to be
hallmark of ongoing autophagy [8]. In general, a high
concordance between BECLIN 1 and LC3 positivity was
observed in the largemajority of the cases. In some cases, LC3
was negative in spite of the positivity for BECLIN 1. This fact
was likely due to the concomitant high expression of BCL-2,
which is known to nullify the autophagy function of BECLIN
1 [22], as was proven in at least some of the cases. We
found that the BECLIN 1-positive cancers associated with the
patients deceased during the study were indeed negative for
vacuolar LC3 staining and highly expressing BCL-2. Though
not statistically relevant because of the small number of
cases, indirectly our finding agrees with that reported by Lin
et al. [18], who showed that low expression of BECLIN 1 in
combination with high expression of BCL-xL predicts a poor
survival in ovarian cancer patients. Of note, also LC3 posi-
tivity significantly correlated with patient’s overall survival at
5 years after diagnosis, thus supporting the contention that
the patients bearing a tumour with a high proportion of
autophagy-active cells had a better prognosis. In this regard, it
is to bementioned that, in clear cell ovarian cancer histotypes,
but not in other examined histotypes, the high expression of
LC3A was found to significantly correlate with hypoxia and
poor prognosis [20].We could not comparewith this study, as
in our series we had only 4 cases of clear cell carcinomas, 2
each either BECLIN 1 positive or BECLIN 1 negative.
It remains to be explained through which molecular
pathway the ongoing autophagy in cancer cells could turn of
benefit in the chemotherapeutic response so that the patient
experiences a better prognosis. The two-hit model predicts a
synergistic death effect of two proautophagic stimuli [25]. In
fact, although autophagy is in principle a prosurvival path-
way, it might also lead to cell death if dysregulated [12, 23, 26].
In particular, cells in which autophagy is basally upregu-
lated may undergo apoptosis if subjected to an additional
metabolic or genotoxic stress that hyperinduces autophagy
[25]. We hypothesize that autophagy-active cancer cells may
succumb in response to drugs that hyperstimulate autophagy.
This is the rationale for the use of mTOR inhibitors in
ongoing clinical trials for the treatment of ovarian cancers
[7]. With relevance to our chemotherapy protocol, it has
been reported that the transgenic overexpression of BECLIN 1
sensitizes cervical cancer cells to carboplatin and to paclitaxel
by promoting apoptosis and autophagic cell death [27, 28].
BECLIN 1 and BCL-2 occupy a central role in the com-
plex cross-talk between autophagy and apoptosis [29], and
chemotherapeutic drugs could bemore effective in those cells
with an altered ratio between these two proteins. Consis-
tent with our hypothesis, it was recently shown that the
Src/Abl kinases inhibitor Dasatinib arrested the growth of
ovarian cancer xenograft by inducing BECLIN 1-dependent
autophagic cell death, and hyperstimulation of autophagywas
associated with downregulation of BCL-2 expression [30].
BioMed Research International 9
This could also explain the poor survival reported in women
bearing an ovarian cancer expressing low level of BECLIN 1
and high level of BCL-xL [17]. Besides, the high expression
of BECLIN 1 could enhance the cytotoxic response to a
chemotherapeutic drug in ovarian cancer cells also via an
autophagy-independent mechanism [31]. Additionally, the
hypothesis that tumour with intrinsic high level of basal
autophagy may have a better prognosis even without chemo-
therapy cannot be excluded.Thoughwe could not test directly
this hypothesis, we note that of the 7 patients for whom
chemotherapy was not deemed (because they were staged as
pT1 and the tumour was of grade 1) 6 were bearing a BECLIN
1-positive tumour andunderwentCR,whereas 1was bearing a
BECLIN 1-negative tumour and was DOD.
In conclusion, while on one hand the upregulation of
basal autophagy associated with a higher ratio of BECLIN 1
versus BCL-2 proteins expression enables the cancer cells to
overcome the metabolic stresses caused by the lack of oxygen
and nutrients, it on the other hand also renders these cells
more susceptible to chemotherapeutic drugs that overstimu-
late autophagy. Given the role of mitochondria in the apop-
totic response to chemotherapeutics [32], we suspect that in
the latter case apoptosis ensues because of the exaggerated
mitophagy. Thus, to improve the chance to cure ovarian
carcinomas, one should carefully consider whether to employ
autophagy inhibitors or autophagy-enhancer drugs in the
chemotherapy cocktail depending on the ratio of BECLIN 1
and BCL-2 expression and the actual level of autophagy in the
cancer cells.
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